Ignite Creation Date:
2025-12-25 @ 4:26 AM
Ignite Modification Date:
2025-12-26 @ 3:29 AM
Study NCT ID:
NCT06846320
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2025-02-21
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000098647', 'term': 'Generalized Anxiety Disorder'}], 'ancestors': [{'id': 'D001008', 'term': 'Anxiety Disorders'}, {'id': 'D001523', 'term': 'Mental Disorders'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 315}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2025-04-29', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'completionDateStruct': {'date': '2026-11', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-20', 'studyFirstSubmitDate': '2025-02-21', 'studyFirstSubmitQcDate': '2025-02-21', 'lastUpdatePostDateStruct': {'date': '2025-12-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2025-02-26', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-11', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants with Adverse Events (AEs)', 'timeFrame': 'Up to approximately 10 weeks', 'description': 'An AE is defined as any untoward medical occurrence in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.'}, {'measure': 'Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score', 'timeFrame': 'Up to approximately 6 weeks', 'description': "The HAM-A is a 14-item, clinician-reported measure used to quantify and categorize the participant's anxiety over the past week. Items are rated on a 5-point Likert rating scale. The HAM-A total score ranges from 0 to 56, with higher scores indicating greater anxiety severity."}], 'secondaryOutcomes': [{'measure': 'Change from Baseline in Penn State Worry Questionnaire-10 (PSWQ-10) Total Score', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'The PSWQ-10 is a 10-item, participant-reported measure of the tendency of an individual to worry, the excessiveness or intensity of worry, and the tendency for the worry to be generalized and not restricted to a small number of situations. Items are rated from 0 to 6 (0, never; 6, almost always). Total scores range from 0 to 60, with higher scores indicating greater worry.'}, {'measure': 'Change from Baseline in Clinical Global Impression of Severity Scale (CGI-S) Generalized Anxiety Disorder (GAD)', 'timeFrame': 'Up to approximately 6 weeks', 'description': "The CGI-S GAD is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the participant population. The measure uses a 5-point Likert rating scale, with higher scores indicating greater anxiety severity."}, {'measure': 'Change from Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score', 'timeFrame': 'Up to approximately 4 weeks', 'description': "The HAM-A is a 14-item, clinician-reported measure used to quantify and categorize the participant's anxiety over the past week. Items are rated on a 5-point Likert rating scale. The HAM-A total score ranges from 0 to 56, with higher scores indicating greater anxiety severity."}, {'measure': 'Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score', 'timeFrame': 'Up to approximately 6 weeks', 'description': "The MADRS is a 10-item, clinician-rated scale that evaluates the participant's depressive symptomatology during the past week. Participants are rated on items assessing feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty in concentration, and lack of interest. Each item is scored on a 7-point scale with a score of 0 reflecting no symptoms and a score of 6 reflecting symptoms of maximum severity."}, {'measure': 'Percentage of Participants in Remission', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'Remission is defined as HAM-A total score \\<=7.'}, {'measure': 'Percentage of Participants with HAM-A Response', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'HAM-A response is defined as \\>= 50% reduction from baseline in HAM-A total score'}, {'measure': 'Percentage of Participants with Clinical Global Impression of Change (CGI-C) GAD Responder Status of "Much Better" or "Moderately Better"', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'The CGI-C GAD is a clinician-rated scale that measures the overall change in a participant\'s GAD symptoms since initial receipt of the study medication. The participant is rated on a 7-point Likert scale ranging from "Much better" (1) to "Much worse" (7).'}, {'measure': 'Change from Baseline in Patient Global Impression of Severity Scale (PGI-S) Generalized Anxiety Disorder (GAD)', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'The PGI-S GAD is a single, patient-reported item that assesses the subject\'s perceived level of GAD symptoms over the past 7 days. The measure uses a 5-point Likert rating scale with responses ranging from "no symptoms" (1) to "very severe" (5), with higher scores indicating greater severity of GAD symptoms.'}, {'measure': 'Percentage of Participants with Patient Global Impression of Change Scale (PGI-C) Generalized Anxiety Disorder (GAD) Responder Status of "Much Better" or "Moderately Better"', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'The PGI-C GAD is a single, patient-reported item that assesses the subject\'s perceived overall change in their GAD symptoms since they started taking the study medication. The measure uses a 7-point Likert rating scale with responses ranging from "much better" (1) to "much worse" (7). Higher scores indicate worse GAD symptoms'}, {'measure': 'Change from Baseline in Patient Global Impression of Severity Scale (PGI-S) Worry', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'The PGI-C Worry is a single, patient-reported item that assesses the subject\'s perceived overall change in their worry since they started taking the study medication. The measure uses a 7-point Likert rating scale with responses ranging from "much less worried" (1) to "much more worried" (7). Higher scores indicate more worry.'}, {'measure': 'Percentage of Participants with Patient Global Impression of Change Scale (PGI-C) Worry Responder Status of "Much Better" or "Moderately Better"', 'timeFrame': 'Up to approximately 6 weeks', 'description': 'The PGI-C Worry is a single, patient-reported item that assesses the subject\'s perceived overall change in their worry since they started taking the study medication. The measure uses a 7-point Likert rating scale with responses ranging from "much less worried" (1) to "much more worried" (7). Higher scores indicate more worry.'}]}, 'oversightModule': {'isUsExport': True, 'oversightHasDmc': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['LEGATO - (GAD)', 'Generalized Anxiety Disorder (GAD)', 'ABBV-932'], 'conditions': ['Generalized Anxiety Disorder (GAD)']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.abbvieclinicaltrials.com/study/?id=M25-099', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': 'Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD. The purpose of this study is to assess how safe and effective ABBV-932 is when added to the antidepressant therapies in adult participants with GAD who have had an inadequate response ADTs.\n\nABBV-932 is an investigational drug being developed for the adjunctive treatment of GAD. Participants will be randomly assigned to receive ABBV-932 or Placebo in addition to their currently prescribed ADTs. There is 1 in 3 chance of participants assigned to Placebo. Approximately 315 adult participants with GAD and inadequate response to ADTs will be enrolled in approximately 50 sites in the United States and Puerto Rico.\n\nParticipants will receive oral capsules of ABBV-932 or matching placebo in addition to their prescribed ADT for 6 weeks and then will be followed for an additional 4 week follow-up period.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for generalized anxiety disorder (GAD) confirmed by the Mini International Neuropsychiatric Interview (MINI).\n* Currently taking one of the Food and Drug Administration (FDA) approved antidepressant therapies (ADT) for GAD (i.e., escitalopram, paroxetine, duloxetine, or venlafaxine ER) with an inadequate response to an adequate dose (per label) and duration (\\>= 8 weeks) as verified by a baseline Hamilton Anxiety Rating Scale (HAM-A) total score \\>= 20 and Clinical Global Impression of Severity Scale (CGI-S GAD) \\>= 4.\n\nExclusion Criteria:\n\n* Have a Montgomery-Åsberg Depression Rating Scale (MADRS) score \\>= 20.\n* New diagnosis or exacerbation of major depression in the last 6 months.'}, 'identificationModule': {'nctId': 'NCT06846320', 'briefTitle': 'Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder', 'organization': {'class': 'INDUSTRY', 'fullName': 'AbbVie'}, 'officialTitle': 'A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects With Generalized Anxiety Disorder Who Have Had an Inadequate Response to Antidepressant Therapies', 'orgStudyIdInfo': {'id': 'M25-099'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ABBV-932 Dose A', 'description': 'Participants will receive ABBV-932 dose A in addition to prescribed antidepressant therapies (ADTs).', 'interventionNames': ['Drug: ABBV-932', 'Drug: Antidepressant Therapy (ADT)']}, {'type': 'EXPERIMENTAL', 'label': 'ABBV-932 Dose B', 'description': 'Participants will receive ABBV-932 dose B in addition to prescribed antidepressant therapies (ADTs).', 'interventionNames': ['Drug: ABBV-932', 'Drug: Antidepressant Therapy (ADT)']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo for ABBV-932', 'description': 'Participants will receive placebo for ABBV-932 in addition to prescribed antidepressant therapies (ADTs).', 'interventionNames': ['Drug: Placebo for ABBV-932', 'Drug: Antidepressant Therapy (ADT)']}], 'interventions': [{'name': 'ABBV-932', 'type': 'DRUG', 'description': 'Oral Capsule', 'armGroupLabels': ['ABBV-932 Dose A', 'ABBV-932 Dose B']}, {'name': 'Placebo for ABBV-932', 'type': 'DRUG', 'description': 'Oral Capsule', 'armGroupLabels': ['Placebo for ABBV-932']}, {'name': 'Antidepressant Therapy (ADT)', 'type': 'DRUG', 'description': 'Standard of care', 'armGroupLabels': ['ABBV-932 Dose A', 'ABBV-932 Dose B', 'Placebo for ABBV-932']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35801', 'city': 'Huntsville', 'state': 'Alabama', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '256-551-4431'}], 'facility': 'University of Alabama - Huntsville Regional Medical Campus /ID# 267818', 'geoPoint': {'lat': 34.7304, 'lon': -86.58594}}, {'zip': '85012', 'city': 'Phoenix', 'state': 'Arizona', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Ima Clinical Research Phoenix (Alea) /ID# 275737', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '85704', 'city': 'Tucson', 'state': 'Arizona', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Noble Clinical Research /ID# 267952', 'geoPoint': {'lat': 32.22174, 'lon': -110.92648}}, {'zip': '92805', 'city': 'Anaheim', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '714-999-6688'}], 'facility': 'Advanced Research Center /ID# 267874', 'geoPoint': {'lat': 33.83529, 'lon': -117.9145}}, {'zip': '92324', 'city': 'Colton', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '909-824-2325'}], 'facility': 'Axiom Research /ID# 267814', 'geoPoint': {'lat': 34.0739, 'lon': -117.31365}}, {'zip': '92251', 'city': 'Imperial', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '760-545-0123'}], 'facility': 'Sun Valley Research Center /ID# 267864', 'geoPoint': {'lat': 32.84755, 'lon': -115.56944}}, {'zip': '91945', 'city': 'Lemon Grove', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Synergy San Diego /ID# 267879', 'geoPoint': {'lat': 32.74255, 'lon': -117.03142}}, {'zip': '90807', 'city': 'Long Beach', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Alliance for Research Alliance for Wellness /ID# 267911', 'geoPoint': {'lat': 33.76696, 'lon': -118.18923}}, {'zip': '90015', 'city': 'Los Angeles', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '714-289-1100'}], 'facility': 'NRC Research Institute DTLA /ID# 267832', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Excell Research /ID# 267918', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '92591', 'city': 'Temecula', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Viking Clinical Research Center - Temecula /ID# 268598', 'geoPoint': {'lat': 33.49364, 'lon': -117.14836}}, {'zip': '94596', 'city': 'Walnut Creek', 'state': 'California', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '925-298-5147'}], 'facility': 'Sunwise Clinical Research /ID# 267863', 'geoPoint': {'lat': 37.90631, 'lon': -122.06496}}, {'zip': '06416', 'city': 'Cromwell', 'state': 'Connecticut', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Connecticut Clinical Research - Cromwell /ID# 271241', 'geoPoint': {'lat': 41.5951, 'lon': -72.64537}}, {'zip': '32256', 'city': 'Jacksonville', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Cns Healthcare - Jacksonville /ID# 268588', 'geoPoint': {'lat': 30.33218, 'lon': -81.65565}}, {'zip': '33777', 'city': 'Largo', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '321-878-9477'}], 'facility': 'Accel Research Sites Network - St. Pete /ID# 267821', 'geoPoint': {'lat': 27.90979, 'lon': -82.78842}}, {'zip': '32751', 'city': 'Maitland', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'K2 Medical Research, LLC /ID# 267841', 'geoPoint': {'lat': 28.62778, 'lon': -81.36312}}, {'zip': '33125', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '305-547-2011'}], 'facility': 'GMI Florida - Central Miami Medical Institute /ID# 267839', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33155', 'city': 'Miami', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '305-643-8400'}], 'facility': 'Allied Biomedical Res Inst Inc /ID# 267813', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32803', 'city': 'Orlando', 'state': 'Florida', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Apg Research /ID# 271707', 'geoPoint': {'lat': 28.53834, 'lon': -81.37924}}, {'zip': '30060', 'city': 'Marietta', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Psych Atlanta /ID# 267878', 'geoPoint': {'lat': 33.9526, 'lon': -84.54993}}, {'zip': '31405', 'city': 'Savannah', 'state': 'Georgia', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '912-744-0800'}], 'facility': 'iResearch Savannah /ID# 267865', 'geoPoint': {'lat': 32.08354, 'lon': -81.09983}}, {'zip': '60637', 'city': 'Chicago', 'state': 'Illinois', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University of Chicago Medical Center /ID# 275131', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '66210', 'city': 'Overland Park', 'state': 'Kansas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Collective Medical Research /ID# 272015', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}, {'zip': '20877-1407', 'city': 'Gaithersburg', 'state': 'Maryland', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '301-251-4702'}], 'facility': 'CenExel /ID# 267853', 'geoPoint': {'lat': 39.14344, 'lon': -77.20137}}, {'zip': '01103', 'city': 'Springfield', 'state': 'Massachusetts', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '413-305-1144'}], 'facility': 'Elixia, LLC /ID# 267815', 'geoPoint': {'lat': 42.10148, 'lon': -72.58981}}, {'zip': '63368', 'city': "O'Fallon", 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Psychiatric Care And Research Center /ID# 271701', 'geoPoint': {'lat': 38.81061, 'lon': -90.69985}}, {'zip': '63304', 'city': 'Saint Charles', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'St. Charles Psychiatric Associates /ID# 271202', 'geoPoint': {'lat': 38.78394, 'lon': -90.48123}}, {'zip': '63125', 'city': 'St Louis', 'state': 'Missouri', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Arch Clinical Trials /ID# 267851', 'geoPoint': {'lat': 38.62727, 'lon': -90.19789}}, {'zip': '89102', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Ima Clinical Research Las Vegas (Altea) /ID# 275731', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '89121', 'city': 'Las Vegas', 'state': 'Nevada', 'status': 'COMPLETED', 'country': 'United States', 'facility': 'Duplicate_Oasis Clinical Research, LLC /ID# 267953', 'geoPoint': {'lat': 36.17497, 'lon': -115.13722}}, {'zip': '08540', 'city': 'Princeton', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '609-921-3555'}], 'facility': 'Princeton Medical Institute /ID# 267877', 'geoPoint': {'lat': 40.34872, 'lon': -74.65905}}, {'zip': '08755', 'city': 'Toms River', 'state': 'New Jersey', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Bio Behavioral Health /ID# 267919', 'geoPoint': {'lat': 39.95373, 'lon': -74.19792}}, {'zip': '28211', 'city': 'Charlotte', 'state': 'North Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '980-209-9784'}], 'facility': 'New Hope Clinical Research - Inpatient unit /ID# 267810', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'zip': '44012-1004', 'city': 'Avon Lake', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '440-949-9115'}], 'facility': 'Quest Therapeutics of Avon /ID# 267829', 'geoPoint': {'lat': 41.50532, 'lon': -82.0282}}, {'zip': '45219', 'city': 'Cincinnati', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'University Of Cincinnati Medical Center /ID# 271704', 'geoPoint': {'lat': 39.12711, 'lon': -84.51439}}, {'zip': '43210', 'city': 'Columbus', 'state': 'Ohio', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'The Ohio State University /ID# 267924', 'geoPoint': {'lat': 39.96118, 'lon': -82.99879}}, {'zip': '73116', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Sooner Clinical Research /ID# 267881', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '18103', 'city': 'Allentown', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Lehigh Center for Clinical Research /ID# 267908', 'geoPoint': {'lat': 40.60843, 'lon': -75.49018}}, {'zip': '19380-4370', 'city': 'West Chester', 'state': 'Pennsylvania', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '610-891-7200'}], 'facility': 'Suburban Research Associates /ID# 267868', 'geoPoint': {'lat': 39.96097, 'lon': -75.60804}}, {'zip': '29492', 'city': 'Charleston', 'state': 'South Carolina', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '321-878-9477'}], 'facility': 'Coastal Carolina Research Center, LLC /ID# 267826', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '37067', 'city': 'Franklin', 'state': 'Tennessee', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '615-807-4023'}], 'facility': 'Psychiatric Consultants - Franklin /ID# 275133', 'geoPoint': {'lat': 35.92506, 'lon': -86.86889}}, {'zip': '75231', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'FutureSearch Trials of Dallas /ID# 267870', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '75243', 'city': 'Dallas', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Relaro Medical Trials /ID# 270241', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '77407', 'city': 'Richmond', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '346-467-2182'}], 'facility': 'Perceptive Pharma Research /ID# 267836', 'geoPoint': {'lat': 29.58218, 'lon': -95.76078}}, {'zip': '77381', 'city': 'The Woodlands', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Family Psychiatry Of The Woodlands /ID# 275173', 'geoPoint': {'lat': 30.15799, 'lon': -95.48938}}, {'zip': '76309', 'city': 'Wichita Falls', 'state': 'Texas', 'status': 'RECRUITING', 'country': 'United States', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '940-322-1131'}], 'facility': 'Grayline Research Center /ID# 267811', 'geoPoint': {'lat': 33.91371, 'lon': -98.49339}}, {'zip': '98007', 'city': 'Bellevue', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Northwest Clinical Research Center /ID# 267916', 'geoPoint': {'lat': 47.61038, 'lon': -122.20068}}, {'zip': '98201', 'city': 'Everett', 'state': 'Washington', 'status': 'RECRUITING', 'country': 'United States', 'facility': 'Core Clinical Research /ID# 270058', 'geoPoint': {'lat': 47.97898, 'lon': -122.20208}}, {'zip': '00918-3014', 'city': 'San Juan', 'status': 'RECRUITING', 'country': 'Puerto Rico', 'facility': 'INSPIRA Clinical Research /ID# 267822', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}, {'zip': '00918', 'city': 'San Juan', 'status': 'RECRUITING', 'country': 'Puerto Rico', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '787-763-9312'}], 'facility': 'Instituto De Neurologia Dra. Ivonne Fraga, Psc /ID# 267793', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}, {'zip': '00927', 'city': 'San Juan', 'status': 'RECRUITING', 'country': 'Puerto Rico', 'contacts': [{'name': 'Site Coordinator', 'role': 'CONTACT', 'phone': '787-523-9808'}], 'facility': 'BDH Research /ID# 267787', 'geoPoint': {'lat': 18.46633, 'lon': -66.10572}}], 'centralContacts': [{'name': 'ABBVIE CALL CENTER', 'role': 'CONTACT', 'email': 'abbvieclinicaltrials@abbvie.com', 'phone': '844-663-3742'}], 'overallOfficials': [{'name': 'ABBVIE INC.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'AbbVie'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/ourmember/abbvie/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP'], 'timeFrame': 'For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/', 'ipdSharing': 'YES', 'description': 'AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.', 'accessCriteria': 'To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AbbVie', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}